Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Investor Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases September 14, 2024 Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer September 14, 2024 Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium September 9, 2024 Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) All press releases Latest Events Sep 14 2024 Sep 14 2024 Incyte Data Highlights from ESMO 2024 Click here for Webcast Sep 19 2024 Sep 19 2024 Cantor Global Healthcare Conference Click here for Webcast All events
